Tesofensine
Weight Loss, Cognitive, Metabolic Health
In short
- A triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) originally developed for Parkinson and Alzheimer disease.
- Those programmes failed, but trial participants lost weight, which redirected development toward obesity.
- Phase 2 reported roughly 10% weight loss at 24 weeks — substantial for a non-incretin agent.
- Approved in Mexico as Obesium; not approved in the US, EU, or UK.
- Its mechanism is essentially that of a stimulant, and the cardiovascular and psychiatric effects follow accordingly.
Structure
How it works
Tesofensine inhibits reuptake of noradrenaline, dopamine, and serotonin, increasing synaptic concentrations of all three.
Appetite suppression is attributed mainly to the noradrenergic and dopaminergic components acting on hypothalamic feeding circuits, with some contribution from increased energy expenditure.
This places it in the same broad pharmacological family as sibutramine — which was withdrawn worldwide in 2010 after the SCOUT trial showed increased cardiovascular events. That precedent is the most relevant context for evaluating this compound.
What the research shows
The TIPO-1 phase 2 trial reported mean weight loss of about 10.6% at the highest dose over 24 weeks, roughly double what was typical for approved agents at the time.
The Parkinson and Alzheimer programmes both failed on their primary endpoints.
A phase 3 programme was planned. Approval was granted in Mexico; Western regulators have not approved it.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — TIPO-1 phase 2 obesity trial | 0.25, 0.5, or 1.0 mg once daily for 24 weeks | oral | PubMed |
| Human — approved use in Mexico | 0.5 mg daily | oral | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 0.25–0.5 mg daily | oral |
Doses here are small in absolute terms and the compound is potent, so measurement error matters. The 1.0 mg arm in the trial produced the most weight loss and also the most blood pressure and heart rate increase — the dose-response for efficacy and for cardiovascular effect run in the same direction.
Handling and storage
Oral, once daily. The long half-life (around 200 hours has been reported) means levels accumulate substantially over the first weeks and a change takes a long time to fully express.
That long half-life also means a dose you regret does not clear quickly.
Side effects
Dose-dependent increases in heart rate and blood pressure are the defining concern and were seen in the trials.
Common: dry mouth, insomnia, nausea, constipation, and mood changes including irritability and agitation.
The monoamine mechanism carries psychiatric risk — mood disturbance and, theoretically, precipitation of mania in susceptible individuals.
The sibutramine precedent matters here: a similar mechanism, similar cardiovascular signal, and a worldwide withdrawal after a large outcome trial found increased cardiovascular events. No equivalent outcome trial has been completed for tesofensine.
Combinations
Combination with any other serotonergic drug (SSRIs, SNRIs, triptans, MAO inhibitors) risks serotonin syndrome — this is a concrete interaction, not a theoretical one.
Combination with stimulants compounds the cardiovascular effect.
Combination with other monoamine-active compounds in this library, including 9-Me-BC and bromantane, is the specific pattern to avoid.
Research status
Developed by NeuroSearch, with genuine phase 2 data in obesity and failed programmes in neurodegeneration. Later licensed and approved in Mexico.
No cardiovascular outcome trial has been completed, which is the study the sibutramine experience says is necessary.
Legal status
Approved and marketed in Mexico as Obesium. Not approved in the US, EU, UK, Canada, or Australia. Sold in research-chemical channels elsewhere.
WADA status
The mechanism is that of a stimulant, and stimulants are prohibited in competition under WADA class S6. Treat as prohibited and verify against the live list.
Conclusion
Tesofensine produces real weight loss through a real mechanism, and that mechanism is essentially the one that got sibutramine withdrawn worldwide after a cardiovascular outcome trial.
The efficacy is not in doubt. What has not been established is whether the cardiovascular cost is acceptable, and that is the exact question the class has previously answered badly.
Sources
Track your own Tesofensine protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.